We also showed that a high level of ISG20 expression was significantly associated with poor OS in glioma patients, as strengthened by stratification analyses in patient subgroups with differing age, sex, IDH mutation status, 1p19q codeletion status, MGMT methylation, and WHO grade, though the survival difference in G4 subgroup was not statistically significant. This evidence concerns the gene ISG20 and central nervous system cancer.